Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEN1703 in Acute Myeloid Leukemia
NCT03008187Phase 2Completed
- Sponsor
- Menarini Group
- Start
- Mar 2017
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of dapolsertib in acute myeloid leukemia (AML), sponsored by Menarini Group. Started Mar 2017; status: completed.
02
Drugs
dapolsertib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03008187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03008187.